Abstract
Diminished synaptic gain – the sensitivity of postsynaptic responses to neural inputs – may be a fundamental synaptic pathology in schizophrenia. Evidence for this is indirect, however. Furthermore, it is unclear whether pyramidal cells or interneurons (or both) are affected, or how these deficits relate to symptoms. Participants with schizophrenia (Scz, n=108), their relatives (n=57), and controls (n=107) underwent three electroencephalography paradigms – resting, mismatch negativity, and 40 Hz auditory steady-state response – and resting functional magnetic resonance imaging. Dynamic causal modelling was used to quantify synaptic connectivity in cortical microcircuits. Across all four paradigms, characteristic Scz data features were best explained by models with greater self-inhibition (decreased synaptic gain), in pyramidal cells. Furthermore, disinhibition in auditory areas predicted abnormal auditory perception (and positive symptoms) in Scz, in three paradigms. Thus, psychotic symptoms of Scz may result from a downregulation of inhibitory interneurons that may compensate for diminished postsynaptic gain in pyramidal cells.
Competing Interest Statement
RAA, DP, KT, LU, AM, AMH, LC, AS, XMD, HS, PK, GR and KJF have no competing interests to declare. JLJ, JDM and AA consult for RBNC (formerly BlackThorn Therapeutics) and are listed as co-inventors on the following pending patent: Anticevic A, Murray JD, Ji JL: Systems and Methods for Neuro-Behavioral Relationships in Dimensional Geometric Embedding (N-BRIDGE), PCT International Application No. PCT/US2119/022110, filed March 13, 2019. JDM holds stock in BlackThorn Therapeutics. LEH has received or plans to receive research funding or consulting fees on research projects from Mitsubishi, Your Energy Systems LLC, Neuralstem, Taisho, Heptares, Pfizer, Luye Pharma, Sound Pharma, Takeda, and Regeneron. AA is also a SAB member for BlackThorn Therapeutics.
Funding Statement
RAA is an MRC Skills Development Fellow (MR/S007806/1) and has been supported by a UCL Bogue Research Fellowship, the Academy of Medical Sciences (AMS-SGCL13-Adams), the National Institute of Health Research (CL-2013-18-003), and the NIHR UCLH Biomedical Research Centre. JDM is funded by NIH grant MH112746. KJF is funded by the Wellcome Trust (Ref: 088130/Z/09/Z).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Data were collected from studies sponsored by the National Institute of Health (MH085646 and DA027680) and under human subject protocols approved by the University of Maryland, Baltimore, Institutional Review Board (HP-00045716 and HP-00043082) and University College London Research Ethics Committee (4356/003).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data are available upon reasonable request to Prof Elliot Hong.
